Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy

Capricor Therapeutics, which received early funding from CureDuchenne, has shared news of positive interactions with the FDA for their CAP-1002 program for DMD.  Capricor will be having an additional meeting with the FDA in Q2 2024, where they will share data and discuss the plan for submitting a rolling BLA, which might expedite their path to potential drug approval. 

Read the Full Press Release HERE

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.